Immuneering Corp
IMRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001790340
No open-market purchases or sales by Immuneering Corp insiders were filed in the last 90 days; 111 institutions reported holding it in 13F filings for Q2 2026, worth $171.6M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Immuneering Corp changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 38 | 37 | −1 |
| Shares | 12.1M | 12.5M | +395.7K (+3.3%) |
| Value | $316.4M | $200.1M | −$116.3M (−36.8%) |
New holders (4)
Institutions that held Immuneering Corp at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Adage Capital Partners GP, L.L.C. | 314,000 | $5.08M | 0.01% |
| Goldman Sachs Group Inc | 13,162 | $213.0K | 0.00% |
| Allspring Global Investments Holdings, LLC | 9,228 | $149.0K | 0.00% |
| Daiwa Securities Group Inc. | 76 | $1.00K | 0.00% |
Sold out (5)
Institutions that held Immuneering Corp at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Caas Capital Management LP | 40,000 | $1.06M |
| Ghisallo Capital Management LLC | 15,000 | $398.0K |
| Marshall Wace, LLP | 13,149 | $349.0K |
| MetLife Investment Management | 3,719 | $98.7K |
| Metropolitan Life Insurance Co | 2,814 | $74.7K |